These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11323162)

  • 1. Assessment of biotechnology products for therapeutic use.
    Sims J
    Toxicol Lett; 2001 Mar; 120(1-3):59-66. PubMed ID: 11323162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notes to applicants for marketing authorizations on the pre-clinical biological safety testing of medicinal products derived from biotechnology (and comparable products derived from chemical synthesis). Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety of Medicines.
    J Biol Stand; 1989 Jul; 17(3):203-12. PubMed ID: 2677013
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
    Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
    PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety evaluation of biological and biotechnology-derived medicines.
    Dayan AD
    Toxicology; 1995 Dec; 105(1):59-68. PubMed ID: 8638284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety evaluation of biotechnology products.
    Zbinden G
    Drug Saf; 1990; 5 Suppl 1():58-64. PubMed ID: 2182064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Issues with biotechnology products in toxicologic pathology.
    Terrell TG; Green JD
    Toxicol Pathol; 1994; 22(2):187-93. PubMed ID: 7973366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Environmental safety assessment of vaccines derived from biotechnology.
    Pastoret PP; Brochier B; Denis M
    Rev Sci Tech; 1995 Dec; 14(4):963-77. PubMed ID: 8639965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Special considerations for the regulation of biological medicinal products in individualised medicine. More than stratified medicine].
    Müller-Berghaus J; Volkers P; Scherer J; Cichutek K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1538-44. PubMed ID: 24170083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preclinical evaluation of the safety of biotechnology products: specific aspects].
    Descotes J; Ravel G; Vial T
    Therapie; 2003; 58(2):139-43. PubMed ID: 12942854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difficulties in conceiving and applying guidelines for the safety evaluation of biotechnologically-produced drugs: some examples.
    Claude JR
    Toxicol Lett; 1992 Dec; 64-65 Spec No():349-55. PubMed ID: 1471191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Pharmacology Evaluation of Biopharmaceuticals.
    Amouzadeh HR; Engwall MJ; Vargas HM
    Handb Exp Pharmacol; 2015; 229():385-404. PubMed ID: 26091648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials of gene/biotechnology products.
    Röthig HJ
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):539-44. PubMed ID: 7885081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research and development of drugs and biologic entities.
    Piascik MM
    Am J Hosp Pharm; 1991 Oct; 48(10 Suppl 1):S4-13. PubMed ID: 1772113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies.
    Putnam WS; Prabhu S; Zheng Y; Subramanyam M; Wang YM
    Trends Biotechnol; 2010 Oct; 28(10):509-16. PubMed ID: 20691488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimum safety requirements for preclinical testing.
    Dorner F; Barrett PN; Schwartz HP; Eibl H
    Dev Biol Stand; 1993; 81():245-52. PubMed ID: 8174809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host cell proteins in biotechnology-derived products: A risk assessment framework.
    de Zafra CL; Quarmby V; Francissen K; Vanderlaan M; Zhu-Shimoni J
    Biotechnol Bioeng; 2015 Nov; 112(11):2284-91. PubMed ID: 26010760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of approaches to viral safety issues for biological products.
    Lubiniecki AS
    PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotoxicity testing of biotechnology-derived products. Report of a GUM task force. Gesellschaft für Umweltmutationsforschung.
    Gocke E; Albertini S; Brendler-Schwaab S; Müller L; Suter W; Würgler FE
    Mutat Res; 1999 Mar; 436(2):137-56. PubMed ID: 10095137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.